Celltrion Healthcare and Celltrion, two major players in autoimmune disease treatments, have secured a supply agreement worth approximately 423.6 billion won. This contract, the largest quarterly supply deal ever, is driven by the increasing demand for antibody biosimilars in the US and Europe, as well as the recent approvals of Humira biosimilars Uplyma and Begzelma. The company is focused on meeting this growing demand by ensuring fast worldwide delivery.
Furthermore, the addition of Teva’s contract manufacturing (CMO) supply of migraine treatment raw materials is expected to further boost sales in the second half of the year.
In the European market, Celltrion’s Remsima recorded a market share of 61.7%, Truxima 22.1%, and Herzuma 19.2% in the first quarter of this year. Notably, Remsima and Truxima have surpassed the market share of the original products.
Meanwhile, in the US market, Remsima (branded as Inflectra) holds a solid market share of 30.2%, and Truxima holds 30.5% in the second quarter of this year. This is particularly positive for Remsima SC (branded as Zimpentra), the subcutaneous injection formulation of Remsima, as it is currently undergoing the new drug approval process in the US.
In the first quarter of this year, Remsima SC achieved a market share of 17% in the five largest European countries (EU5), with significant growth in Germany (33%) and France (21%). Combined with the market share of Remsima, the two formulations hold a dominant market share of 68.5% in EU5.
Celltrion is also prioritizing the expansion of its market share through newly approved products such as Uplyma and Begzelma in major global countries like the US and Europe. While the company is making progress in the US market, it continues to receive orders from large European countries, including Italy.
A Celltrion official expressed confidence in their product portfolio’s stable growth and pledged to ensure a reliable supply to meet the upcoming expansion of approvals and launch areas.
Reflecting rapid supply volume due to increased demand for similar US-European products and the growth of new items
Sales are expected to grow significantly in the second half of the year with the addition of Teva CMO items.
Remsima’s progress in the US continues ahead of the approval of new drug ‘Zympentra’… 2nd quarter market share was recorded at 30.2%
Uplaima-Begzelma are also cruises to land in the United States… Orders continue to come from major European countries, including Italy.
[바이오타임즈] Celltrion Healthcare and Celltrion, along with autoimmune disease treatments ‘Remsima’, ‘Remsima SC’, and ‘Uplyma’, blood cancer treatment ‘Truxima’, breast cancer treatment ‘Herzuma’, non-small cell lung cancer and treatment of metastatic colorectal cancer. He announced on the 25th that he had signed a supply agreement worth around 423.6 billion won, including ‘Begzelma’.
This contract is the largest ever for a quarterly supply contract, and growth is being driven by continued growing demand for antibody biosimilars in the US and Europe and new items such as Humira biosimilars Uplyma and Begzelma, which have u recently approved for sale in major global companies. Accordingly, the quantity is for fast worldwide delivery.
In addition, if TEVA’s contract manufacturing (CMO) supply of migraine treatment raw materials is added within the year, sales in the second half of the year are expected to increase further.
According to pharmaceutical market research company IQVIA and Celltrion Healthcare, Celltrion’s representative autoimmune disease treatment Remsima recorded a market share of 61.7%, Truxima 22.1%, and Herzuma 19.2% in the European market in the first quarter of this year. In particular, Remsima and Truxima lead the market with a solid market share that exceeds that of the original product.
In the US market, as of the second quarter of this year, Remsima (US brand name: Inflectra) maintains a solid market share, achieving a 30.2% share and Truxima a 30.5% share.
In particular, as Remsima SC (US brand name: Zimpentra), a subcutaneous injection formulation of Remsima, is currently undergoing the new drug approval process in the US, Remsima’s steady increase in market share is positive for Zimfentra’s future entry into the US market. It is expected to act as a
From the first quarter of this year, Remsima SC continues to grow, recording a market share of 17% in five large European countries (EU5). In particular, it is growing rapidly, achieving a market share of 33% in Germany and 21% in France.
Remsima SC is growing at the fastest rate compared to blockbuster new drugs recently launched in Europe, and the combined market share of Remsima and Remsima SC in EU5 reaches 68.5%.
Celltrion is also working rapidly to expand its market share focusing on new products such as Uplyma and Begzelma, which are recently gaining approval in major global countries such as the United States and Europe.
Recently, although the process for settling into the US market has been going smoothly, in Europe, the company has been constantly receiving orders from large countries such as Italy.
A Celltrion official said, “While the supply of biosimilar products such as Remsima and Herzuma is expanding, next-generation products such as Remsima SC and Uplyma are achieving stable growth as approvals and orders continue to expand.” “We will do our best to ensure a stable supply as the growth in the second half of the year is expected to continue next year due to the expansion of approval and launch areas,” he said.
[바이오타임즈=정민아 기자] news@biotimes.co.kr
Copyright © BioTimes Reproduction and redistribution prohibited.
#Celltrion #signs #KRW #billion #supply #deal #Celltrion #Healthcare #biggest #quarter
